All In Biotech

Drug Trial Radar · NCT07099989

Pharmacokinetics of Zelquistinel in Fasted or Fed State

A Randomized, Open-Label, 2-Cohort, 2-Period Crossover Study to Evaluate the Pharmacokinetics of GATE-251 (Zelquistinel), 3 and 10 mg, Under Both Fasted and Fed Conditions in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jul 24, 2025

Primary completion

Feb 5, 2026

Study completion Jul 2026

Sponsor

Lead sponsor
Syndeio Biosciences, IncIndustry
Sponsor type
Industry
Collaborators
Dr. Vince Clinical Research
First posted
Aug 1, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 59 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to assess the effect of food on the rate and extent of absorption of a single dose of Zelquistinel 3 mg or 10 mg oral tablets tablets in healthy adult volunteers.

Conditions

  • Healthy Volunteers in Fed and Fasted State

Interventions

  • Zelquistinel 3 mgDrug

    Subjects will receive Zelquistinel 3 mg in fed and fasted state (high fat meal).

  • Zelquistinel 10 mgDrug

    Subjects will receive Zelquistinel 10 mg in fed and fasted state (high fat meal).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic parameter Maximum Concentration (Cmax) in plasmaTime frame: Hour zero to Hour 24
  2. Pharmacokinetic parameter Area Under the Curve (AUC) for Concentration in plasma over timeTime frame: Hour 0 to hour 24
  3. Pharmacokinetic parameter Maximum Concentration (Cmax) in cerebrospinal fluidTime frame: Hour 0 to Hour 24
  4. Pharmacokinetic parameter Area Under the Curve (AUC) for concentration in cerebrospinal fluid over timeTime frame: Hour 0 to hour 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dr. Vince Clinical Research

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.